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Low-level viremia during antiretroviral therapy and its accurate measurement are increasingly relevant. Here, we present an in-
ternational collaboration of 4,221 paired blood plasma viral load (pVL) results from four commercial assays, emphasizing the
data with low pVL. The assays compared were the Abbott RealTime assay, the Roche Amplicor assay, and the Roche TaqMan
version 1 and version 2 assays. The correlation between the assays was 0.90 to 0.97. However, at a low pVL, the correlation fell to
0.45 to 0.85. The observed interassay concordance was higher when detectability was defined as 200 copies/ml than when it was
defined as 50 copies/ml. A pVL of100 to 125 copies/ml by the TaqMan version 1 and version 2 assays corresponded best to a
50-copies/ml threshold with the Amplicor assay. Correlation and concordance between the viral load assays were lower at a low
pVL. Clear guidelines are needed on the clinical significance of low-level viremia.
The level of HIV-1 RNA in blood plasma (viral load) is arguablythe most important surrogate marker in the treatment of HIV
infection (1). For over a decade, the endpoint PCR-based Roche
Cobas Amplicor HIV-1 Monitor test (versions 1 and 1.5) (Ampli-
cor) (2) was a widely used viral load assay and was in use in both
clinical trials and routine practice. Many clinical trials have used a
viral load considered to be “undetectable” by the Amplicor assay
(i.e., one that is 50 HIV-1 RNA copies/ml) as the endpoint for
measuring the efficacy of antiretroviral therapy. Various guide-
lines have adopted the same threshold as the goal of therapy for all
patients, regardless of previous treatment experience (1, 3–5). Af-
ter many years of using the Amplicor test, the real-time PCR-based
Roche Cobas AmpliPrep/Cobas TaqMan real-time quantitative hu-
man immunodeficiency virus type 1 (HIV-1) test (TaqMan) began to
replace the Amplicor test in early 2008. There are two versions of the
TaqMan assay; version 2 has replaced version 1 across Europe, Asia,
and North America. The TaqMan versions 1 and 2 assays have lower
limits of quantitation of 40 and 20 copies/ml, respectively (6). Other
assays based on real-time PCR technology have also been imple-
mented in clinical settings, including the Abbott RealTime HIV-1
assay (RealTime) (Abbott Molecular, Inc.) and the Qiagen artus
HIV-1 QS-RGQ assay (7, 8), which have lower limits of quantitation
of 40 and 45 copies/ml, respectively (9).
Although generally these assays tend to give roughly compara-
ble results (10), their manufacturers have reported that variation
and error tend to increase at the lower limits of quantitation of the
assays. Furthermore, there have been reports that real-time PCR-
based assays tend to identify more patients as having low-level
viremia than does the Amplicor test (10–15). Multiple studies
have documented variation between these assays when measuring
samples with low viral load levels (6, 13, 15–21).
Therapy outcomes have been shown to be influenced by low-
level viremia in some studies (16, 22–28) but not others (29–32),
in part reflecting differences in the measured outcomes. However,
the overall clinical relevance of low-level viremia remains contro-
versial. Accordingly, some clinical guidelines (4, 33) have set
higher thresholds (200 copies/ml) for defining virologic failure,
while others (1) are more conservative and recommend that pa-
tients with lower levels of viremia be reviewed due to a potential
risk of virological rebound.
A significant clinical question has been to determine the rele-
vance of low-level viremia. In order to properly address this ques-
tion, an assessment of the fundamental agreement of the various
assays for defining low-level viremia must be undertaken. Given
that the viral load assays mentioned above differ in their reported
lower limits of quantitation and detection (LLQ and LLD, respec-
tively) (34), and given the lack of definitive guidelines on the man-
agement of low-level viremia, our aim was to assess the basic compa-
rability of various viral load assays at these lower viral loads. Thus, we
established a large international collaborative group to assemble
comparisons of the Amplicor 1.5, RealTime, TaqMan version 1, and
TaqMan version 2 viral load assays at low viral loads.
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MATERIALS AND METHODS
A total of 14 sites from Europe, North America, and Africa contributed
4,221 paired viral load results obtained by different assays performed us-
ing the same sample. The numbers of data points in the comparisons were
1,384 (Amplicor versus TaqMan version 1), 365 (Amplicor versus TaqMan
version 2), 827 (RealTime versus TaqMan version 1), 1,230 (RealTime versus
TaqMan version 2), and 415 (TaqMan version 1 versus TaqMan version 2).
The subtype data, when provided, were collected independently at each
FIG 1 Comparisons among viral load assays. (A and B) Shown is the correlation of the TaqMan assays with either the Amplicor assay (A) or the RealTime assay
(B). Comparisons involving TaqMan version 1 are shown with filled gray circles, while those involving TaqMan version 2 are shown with open squares. The R2
values for all correlations are shown in the legends. (C to F) The bottom four panels show Bland-Altman difference plots comparing different viral load assays.
Shown are comparisons of the Amplicor assay with the TaqMan version 1 (C) or version 2 (D) assay and of the RealTime assay with the TaqMan version 1 (E)
or version 2 (F) assay. The bias (mean difference between the assays) is shown as a solid horizontal line, and the 95% limits of agreement are shown with dashed
lines at1.96 standard deviations.
Swenson et al.
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site by various in-house methods. Ethical approval at the individual col-
laborating centers was based on local regulations. There were insufficient
numbers of paired results from both the Amplicor and RealTime tests, so
comparisons between them were excluded. Correlation and Bland-Alt-
man analyses were performed using paired data points. If a viral load value
fell below the LLQ of a given assay or was classified as not detected, the
value was imputed as 1 copy less than the LLQ (e.g., 49 for an LLQ of 50
copies/ml).
RESULTS
The correlations between the viral load assays performed on the
same sets of samples are shown in Fig. 1A and B. Compared to the
Amplicor assay, the TaqMan version 1 assay had a correlation
coefficient (Pearson’s R value) of 0.90, and the TaqMan version 2
assay had an R value of 0.97. The correlation coefficients of the
TaqMan version 1 and version 2 assays were also 0.90 and 0.97
compared to the RealTime assay. Although there were a small
number of data points comparing the Amplicor and RealTime
tests (n  56), these assays had a correlation coefficient of 0.88
(data not shown).
We then restricted our analyses to samples where at least one
assay gave a viral load result of1,000 copies/ml, which is a com-
mon definition of low-level viremia. The lower correlation coeffi-
cients were obtained when the analyses were performed on low-
level viremia samples (Table 1). For example, at 1,000 copies,
the RealTime and TaqMan version 2 assays had R values of ap-
proximately 0.8 compared with anR value of 0.97 for the compar-
ison over the full range of viral load values. All correlations be-
tween the assays were lower when the data were restricted to viral
loads of1,000 copies/ml (Table 1).
Since correlation coefficients do not account for the fact that
one assay may provide consistently higher or lower values relative
to the other assay, pairwise Bland-Altman plots were used to fur-
ther assess the level of agreement (Fig. 1C to F). The 95% level of
agreement ranged from0.61 to 0.75 log when the TaqMan ver-
sion 1 assay was compared with the Amplicor assay (with 55/1,384
[4%] samples outside this range) and ranged from1.2 to 1.0 log
when the RealTime test was compared with the Amplicor test
(with 33/827 [4%] samples outside this range). Samples outside
the 95% level of agreement were mostly due to relative underre-
porting for the TaqMan version 1 test (40 samples and 33 samples
for the two comparisons described above, respectively). For the
TaqMan version 2 test, the 95% level of agreement versus the
Amplicor test was 0.89 to 0.85 (with 1/365 [0.3%] samples be-
low and 14/365 [4%] samples above this range) and versus the
RealTime assay was0.80 to 0.60 (with 19/1,230 [1.5%] samples
below and 43/1,230 [3.5%] samples above this range). Comparing
the TaqMan version 1 and version 2 assays, approximately 4%
(16/415) of the results fell outside the 95% level of agreement, all
due to relative underreporting for the TaqMan version 1 test (data
not shown).
As previously reported (35), HIV subtype may have partially
contributed to assay discordance. The HIV subtype was available
for 1,493 of the 4,221 samples (35%). Analyses involving the Am-
plicor assay were excluded due to a low proportion having HIV
subtype information (10% [175/1,749]). Of 25 samples for which
the TaqMan version 1 test gave results of at least 1.5 log copies
below those of the RealTime test, the most common subtypes were
CRF02 (8 samples), subtype F (5 samples), subtype B (4 samples),
CRF01 (3 samples), CRF09 (2 samples), CRF14 (2 samples), and
subtype G (1 sample). Of 3 samples for which the TaqMan version
2 results were1.5 log copies below those of the RealTime test, the
subtypes were C, CRF01, and CRF02. There were 7 samples that
TaqMan version 1 underquantified by1.5 log compared to Taq-
Man version 2; 6 of these were CRF02 and 1 was subtype G.
Next, we analyzed assay discordance at a threshold of either 50
or 200 copies/ml (Tables 2 and 3). There was higher concordance
between the assays when detectability was defined as 200 cop-
ies/ml than when defined as 50 copies/ml. Overall, 27% (63/
230) and 13% (73/569) of the samples with RealTime assay results
of50 copies/ml were above the 50-copies/ml threshold using the
TaqMan version 1 and TaqMan version 2 assays, respectively, with
median (range) HIV-1 RNA levels of 84 (50 to 394) copies/ml and
99 (51 to 1,620) copies/ml, respectively. For samples with Ampli-
cor assay viral loads of50 copies/ml, 73% (598/819) of the sam-
ples were 50 copies/ml by the TaqMan version 1 assay and 6%
TABLE 1 Correlation coefficients for interassay comparisons at viral
loads of1,000 copies/mla
Assay detection
(at1,000
copies/ml)
Correlation coefficients of discordant results of1,000
copies/ml
Amplicor RealTime TaqMan v1 TaqMan v2
Amplicor NAb 0.52 0.85
RealTime NA 0.74 0.82
TaqMan v1 0.45 0.54 0.69
TaqMan v2 0.80 0.78 0.68
a Correlation coefficients of the interassay comparisons were calculated using the results
with a restriction of at least one viral load assay giving a result of1,000 copies/ml. The
assay restricted to1,000 copies/ml is shown in the left-hand column, and its
comparator assay is indicated in the columns. For example, when TaqMan v1 was
restricted to values of1,000 copies/ml, the matching Amplicor test results had an R
value of 0.45. Conversely, when the Amplicor test was restricted to1,000 copies/ml,
the matching TaqMan v1 results had an R value of 0.52.
b NA, not available.
TABLE 2 Discordance for HIV-1 RNA levels at50 copies/ml
Assay
(at50
copies/ml)
% discordant results of50 copies/ml (no. of discordant
samples/total no. of samples)a
Amplicor RealTime TaqMan v1 TaqMan v2
Amplicor NA 73 (598/819) 6 (10/172)
RealTime NA 27 (63/230) 13 (73/569)
TaqMan v1 11 (27/248) 23 (49/216) 24 (50/206)
TaqMan v2 5 (8/170) 7 (40/356) 25 (51/207)
a Shown are the percentages of results that were discordant between the assays at a
threshold of 50 copies/ml. NA, not available.
TABLE 3 Discordance for HIV-1 RNA levels at200 copies/mla
Assay
(at200
copies/ml)
% discordant results of200 copies/ml (no. of discordant
samples/total no. of samples)
Amplicor RealTime TaqMan v1 TaqMan v2
Amplicor NA 5 (58/1,161) 3 (7/204)
RealTime NA 10 (37/356) 7 (49/728)
TaqMan v1 7 (85/1,188) 16 (59/378) 7 (25/236)
TaqMan v2 3 (7/204) 3 (22/701) 1 (3/314)
a Shown are the percentages of results that were discordant between the assays at a
threshold of 200 copies/ml. The percentage of discordant samples decreased for all
comparisons when a threshold of 200 copies/ml was used, compared to a 50-copies/ml
threshold. NA, not available.
Viral Load Assay Comparison
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FIG 2 Proportion of samples with50 copies/ml by the Amplicor assay as a function of the TaqMan version 1 or version 2 assay. The proportion of samples with
Amplicor results of50 copies/ml decreased at higher TaqMan version 1 and version 2 strata. (A) Proportion of samples with undetectable viral loads by the
Amplicor assay (50 copies/ml) as a function of the viral load reported by the TaqMan version 1 assay. (B) Similar plot as in panel A but as a function of the viral
load reported by the TaqMan version 2 assay. For both TaqMan assays, when either had a viral load result of up to 100 copies/ml, a majority of the corresponding
samples were actually undetectable by the Amplicor assay.
Swenson et al.
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(10/172) of the samples were50 copies/ml by the TaqMan ver-
sion 2 assay, with median (range) HIV-1 RNA levels of 76 (50 to
247) copies/ml and 85 (70 to 164) copies/ml, respectively. Inter-
assay discordance decreased substantially when a 200-copies/ml
threshold was used (Table 3). For example, the discordance be-
tween the Amplicor and TaqMan version 1 assays dropped from
73% at a 50-copies/ml threshold to 5% at a 200-copies/ml thresh-
old.
Consistent with the findings of higher concordance at higher
thresholds, the percentage of results with 50 copies/ml by the
Amplicor test decreased in a stepwise pattern as the reported viral
load using the TaqMan version 1 test increased (Fig. 2A). The
point at which the proportion of Amplicor test results with 50
copies/ml reached a majority of samples occurred in the range of
100 to 124 copies/ml according to the TaqMan version 1 test. In
other words, most samples (71%) with TaqMan version 1 test
results up to 125 copies/ml were actually50 copies/ml according
to the Amplicor test, with a median of 49 copies/ml (interquartile
range [IQR], 49 to 59). For the TaqMan version 2 test, this thresh-
old was approximately 100 copies/ml (Fig. 2B).
DISCUSSION
We present here a large comparison of 4,000 paired viral load
assay results. We also assessed interassay discordance at low viral
load thresholds and found a lower interassay correlation at viral
loads of1,000 copies/ml, compared to the full dynamic ranges of
the assays. This range is of clinical importance since many patients
are on suppressive or near-suppressive antiretroviral therapies.
Indeed, in this study, we deliberately sought a high number of low
viral load data points in order to assess the concordance between
the assays when performed near their lower limits of quantitation.
We found that correlation between the assays was lower at low
viral loads. Discordance decreased when a threshold of 200 cop-
ies/ml was used rather than when a 50-copy threshold was used. As
was previously reported (19, 36), we confirm that the TaqMan
version 2 assay does not appear to have the severe underquantifi-
cation reported with the TaqMan version 1 assay. However, both
TaqMan assays have higher rates of detectability than the Ampli-
cor and RealTime assays. There are a number of factors that may
contribute to assay discordance, including viral blips, sample han-
dling, contamination, or differences in the assay primers used (14,
31, 37–42). Furthermore, the assays themselves have inherently
lower precision, reproducibility, and sensitivity at the lower ends
of their dynamic ranges, which likely contributes to interassay
disagreement at low viral loads. Assays exist to quantify viral loads
even to single-copy levels, and commercial assays can be modified
to accommodate low viral loads (43–46). However, these often
require large volumes of blood plasma, up to 30 ml in some cases
(43), and this precludes their routine use in the clinic setting.
Our data also indicate that a viral load of approximately 100 to
125 copies/ml according to the TaqMan version 1 or TaqMan
version 2 assays may correspond to a threshold of detectability of
50 copies/ml by the Amplicor assay, an HIV viral load assay that
was widely used for10 years. Further, we found that interassay
concordance for all viral load assays is much higher at a 200-
copies/ml threshold than at a 50-copies/ml threshold. Some HIV
clinical guidelines (4, 33) have defined higher cutoffs of 200 to 250
copies/ml for low-level viremia, partially in response to the higher
rates of detectability seen with this next generation of assays. Thus,
the prevalence and extent of low-level viremia may depend a great
deal on the specific viral load assay in use, and the clinical rele-
vance of the detectable viral load may likewise vary with the assay
and threshold defining what is detectable.
The strengths of this data set are its size and the focus on low
viral loads that are close to the limits of detection of the assays, but
there are also some limitations which should be acknowledged.
While the focus of this study was on low viral load levels, there is
also variation at the high viral load strata (47). As this was an
international collaboration, various methods were used to gener-
ate the assay results, and biases inherent in the collections of con-
venience sample sets in some centers may have had unknown
effects. Selection bias may have also influenced the results; for
instance, the Vancouver site deliberately retested samples with the
Amplicor assay that had TaqMan version 1 assay viral loads of
250 copies/ml (29). The handling procedures varied at different
sites as well, and this has been known to impact the results (48),
even though all the laboratories reported using EDTA tubes for
sample collection and storage. The lack of clinical follow-up for
patients experiencing low-level viremia makes the interpretation
of these results difficult to situate in a clinical context. Finally,
older assays were examined in this study. The TaqMan version 1
assay is being phased out or is no longer in use, and the Amplicor
assay has been discontinued. However, although comparisons to
the Amplicor assay are of limited relevance to current practice,
they are essential to contextualizing newer assays, since the Am-
plicor assay has dominated the field for so long.
Additional data are needed to determine the impact of low-
level viremia on outcomes, such as higher viral rebound, CD4
count, therapy changes, and drug resistance, as well as what the
cost impacts are for recalling patients for retesting and changing
treatment (41). The high variability around the threshold of de-
tectability of the viral load assays should be noted, since many
patients have viral loads in this range. This variability makes de-
fining low-level viremia itself difficult to achieve. We found that
agreement between these assays was improved using a 200-cop-
ies/ml threshold. Indeed, this threshold is consistent with the cur-
rent HIV treatment guidelines from the Department of Health
and Human Services (DHHS) (4). However, this study does not
include clinical follow-up, making firm clinical guidelines difficult
to establish based on these data. We suggest that similar large-scale
collaborations focusing on low-level viremia that are paired with
clinical follow-up would be extremely valuable in establishing
such clinical guidelines.
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